Beckman Coulter to Acquire Agencourt Bioscience
Beckman Coulter, Inc. announced plans to acquire Agencourt Bioscience Corporation. Terms of the agreement include a payment at closing of $100 million and up to $40 million of contingent payments through 2007. The acquisition is targeted to close near the end of May 2005. Agencourt's 2004 sales were about $27 million.
Agencourt's patented Solid Phase Reversible Immobilization (SPRI®) technology provides state-of-the-art results for the isolation and purification of RNA and DNA. This robust and proven technology is in daily use with Beckman Coulter's Biomek® automated liquid handling systems in Agencourt's genomic services business and was used to prepare sequencing samples for more than one third of the human genome. Beckman Coulter plans to use SPRI in automated sample preparation systems for biomedical research and molecular testing.
"Agencourt will become a Beckman Coulter center of excellence for nucleic acid science," said Elias Caro, president of the Biomedical Research Division of Beckman Coulter. "In addition to the SPRI technology, this acquisition brings talented scientists and a services business that will give us a real-time window into evolving customer needs. Joining with Agencourt furthers our strategy of providing the best solutions for simplifying and automating laboratory processes."
Other news from the department business & finance
